Urine and endocervical samples were equally good for detecting chlamydial infections during pregnancy.
Nucleic acid amplification testing (NAAT) for Chlamydia trachomatis can be performed in urine samples as well as endocervical samples, thereby facilitating screening by obviating the need for pelvic examinations. However, accuracy of NAAT for chlamydia has not been evaluated during pregnancy. Investigators tested paired endocervical and urine samples obtained during the same clinic visit in 2018 pregnant women (range, 35–37 weeks' gestation) using the Aptima Combo 2 Assay.
In all, 83 tests were positive for both urine and endocervical samples, 3 were positive for endocervical samples only, and 1932 were negative for both samples. Chlamydia prevalence was 4.3% with endocervical samples and 4.1% with urine samples, and statistical testing was …
Reviewing Author
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)